

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 6, 2016**

**SCYNEXIS, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**

(State or other jurisdiction  
of incorporation)

**001-36365**

(Commission  
File Number)

**56-2181648**

(IRS Employer  
Identification No.)

**101 Hudson Street, Suite 3610**

**Jersey City, New Jersey 07302-6548**

(Address of principal executive offices, including zip code)

**(201) 884-5485**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01 Regulation FD Disclosure.**

SCYNEXIS, Inc. (the "Company") will be attending investor conferences and conducting investor meetings during the first quarter of 2016. In connection with these meetings, the Company intends to discuss the slide presentation attached as Exhibit 99.1 (the "Corporate Presentation") to this current report on Form 8-K (the "Current Report"). The Company's current development strategy and outlook for its lead product candidate, SCY-078, is described in the Corporate Presentation.

In accordance with General Instruction B.2. of Form 8-K, the information contained in Item 7.01 in this report (including the Corporate Presentation) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall the Corporate Presentation be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. This Current Report will not be deemed a determination or an admission as to the materiality of any information in the Corporate Presentation that is required to be disclosed by Regulation FD.

**Item 9.01 Financial Statements and Exhibits.**

<u>Exhibit No.</u>	<u>Description</u>
99.1	Corporate Presentation

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**SCYNEXIS, Inc.**

Dated: January 6, 2016

By:           /s/ Eric Francois            
Eric Francois  
Chief Financial Officer

---

## EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Corporate Presentation



*A New Path for Antifungal Treatments*

## Investor Presentation

January 2016




# Forward-looking Statements

---

Certain statements regarding SCYNEXIS, Inc. (the “Company”) made in this presentation constitute forward-looking statements, including, but not limited to, statements regarding our business strategies and goals, plans and prospects, market size, adoption rate, potential revenue, clinical validity and utility, growth opportunities, future products and product pipeline. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risk and uncertainties include, but are not limited to: our ability to successfully develop SCY-078, including our ability to obtain FDA approval for SCY-078; the expected costs of studies and when they will begin; and our reliance on third parties to conduct our clinical studies. Forward-looking statements may be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “could,” “should,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent reports filed with the Securities and Exchange Commission (“SEC”) including under the caption “Risks Factors” in the Company's quarterly report on Form 10-Q or annual report on Form 10-K, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation, or to reflect actual outcomes.

# SCYX: A New Path for Antifungal Treatments

---



# SCYX: Highlights

---



- SCY-078, a new antifungal class with a novel combination of attributes:
  - Validated mechanism of action
  - Both IV and oral formulations
  - Activity against Azole- and Echinocandin-resistant strains
  - Targeting multiple indications
  - Data from two Phase 2 studies expected in 2Q 2016
  - Extended market exclusivity and IP protection
- Significant unmet medical needs with global market potential
- Favorable regulatory environment
  - Granted QIDP and Fast Track status
- Experienced management team
- Expected sufficient funds into 1H 2017 - \$53.8mm in cash (as of 9/30/15)



# SCY-078: A New Antifungal Class

---

IV and oral formulations enable optimal flexibility for in- and out-patient treatment and to target other indications such as Invasive Aspergillosis and refractory fungal infections



# Experienced Senior Management Team


Management team with significant experience in drug development and commercialization

- Developed more than 40 drugs – more than 10 of them in anti-infectives / antifungals

<p>Marco Taglietti, MD Chief Executive Officer</p>		<p><b>Selected Drugs</b></p> 
<p>David Angulo, MD Chief Medical Officer</p>		
<p>Eric Francois Chief Financial Officer</p>		

# 2015: A Year of Transition for SCYX

## From Contract Service Business Organization to Pharma Biotech



# Favorable Environment for Anti-infectives


---

- Positive impact of GAIN Act (July 2012) and pending legislation (DISARM, ADAPT, 21<sup>st</sup> Century Cures):

1. Faster development and approval process
2. Increased access to regulatory agencies
3. Additional 5 years of market exclusivity
4. Potential for better reimbursement

- Developing anti-infectives is typically less risky than other therapeutics
  - Pathogen is an external target
  - *In vitro and in vivo* models are highly predictive
  - Well-established PK/PD models
- $\beta$ -(1-3)-glucan synthase inhibitors recommended for 1<sup>st</sup> line treatment of invasive candidiasis in EU/US Clinical Guidelines
  - Moving away from Azoles in Invasive Candidiasis

# Evolution of the Antifungal Landscape



\* Numbers indicate Peak year WW sales  
Data on File (Study commissioned by the  
Company, IMS Consulting Group, 2015)

# SCY-078: A New Path for Antifungal Therapy

## Moving beyond Azoles and Echinocandins

Selected Product Attributes	Azoles	SCY-078 *	Echinocandins
Oral Formulation	✓	✓	✗
IV Formulation	✓	✓	✓
"Cidal" Activity vs. <i>Candida</i>	✗	✓	✓
Active vs. Azole-Resistant	✗	✓	✓
Active vs. Echinocandin-Resistant	✗	✓	✗
1 <sup>st</sup> Line Invasive Candidiasis **	✗	✓	✓
1 <sup>st</sup> Line Aspergillosis **	✓	✓	✗
1 <sup>st</sup> Line VVC **	✓	✓	✗
Approved Therapy for rVVC	✗	✓	✗
Limited Drug-Drug Interaction	✗	✓	✓
Limited/No QT effect	✗	✓	✓


\* Target attributes for SCY-078

\*\* Indicates primary recommended therapy for selected indication.


# SCY-078: A New Class with Novel Attributes

- $\beta$ -(1-3)-glucan synthase inhibitor antifungal
- A triterpene chemically distinct from Echinocandins
- First non-Azole with IV and oral dosing in clinics
- Oral formulation currently in Phase 2
  - 7 Phase 1 studies in ~100 healthy subjects
  - Linear, well-characterized PK
  - Well-tolerated, once daily dosing
- IV formulation currently in Phase 1
- Activity against *Candida* and *Aspergillus* spp
  - Including Azole- and Echinocandin-resistant strains
- Manageable drug-drug interactions
- QIDP and Fast Track status designation for oral formulation
- 10-year market exclusivity with composition-of-matter patent protection until mid-2030s

SCY-078




Caspofungin



# SCY-078: Validated Mechanism of Action

- SCY-078 targets synthesis of  $\beta$ -(1,3)-glucan in fungal cell wall
  - Mechanism validated by echinocandins
  - Disruption of fungal cell wall with fungicidal effect in *Candida*
  - No  $\beta$ -(1,3)-glucan in human cells, therefore no direct human cell toxicity
  - No cross-resistance with Azoles because of different mechanism



Adapted by Kartsonis et al, *Drug Resistance Update*, 2003  
Anderson Freitas Pinheiro et al. *International Journal of Quantum Chemistry*, 2012



# SCY-078: Microbiology Profile

SCY-078 has shown broad activity against *Candida* and *Aspergillus* spp. including multi-drug resistant *Candida* strains and Azole-resistant *Aspergillus* strains


	MIC <sub>90</sub> µg/mL (MIC range)	Fluconazole	Caspofungin	SCY-078
Wild-type <i>Candida</i> spp.	<i>C. albicans</i> (29)	≥128 (0.06 - ≥128)	2 (0.015 - 8)	1 (0.06 - 2)
	<i>C. glabrata</i> (29)	≥128 (2 - ≥128)	16 (0.03 - 16)	2 (0.5 - 2)
Multi-drug resistant <i>Candida</i> spp.	<i>C. albicans</i> (4)	16 - ≥128	2 - 8	0.12 - 1
	<i>C. glabrata</i> (4)	64 - ≥128	2 - 16	1
	MEC/MIC <sub>90</sub> µg/mL (MIC range)	Amphotericin B	Caspofungin	SCY-078
Wild-type <i>Aspergillus</i> spp.	<i>A. fumigatus</i> (21)	2 (1-2)	0.06 (0.015-0.25)	0.25 (0.03-1)
	<i>A. flavus</i> (23)	2 (1-2)	0.03 (≤0.008-0.03)	0.12 (0.06-0.12)
	<i>A. terreus</i> (18)	2 (1-4)	0.06 (≤0.008-0.06)	0.12 (0.03-0.25)
Azole-resistant* <i>Aspergillus</i> strains	<i>A. fumigatus</i> (6)	1	0.015 - 0.06	0.03 – 0.5

MEC/MIC that encompasses 90% of isolates tested by CLSI broth microdilution method

\* itraconazole-resistant *Aspergillus* spp. (MIC, 4 g/ml) as determined by CLSI broth microdilution methods

Pfaller M. A and Col., J. Antimicrobial Agents and Chemotherapy, 2013; 68(4); 858-863 & 2013; 57(2); 1065-1068.

# SCY-078 Targets Multiple Infections




\* Data on File (Study commissioned by the Company, IMS Consulting Group, 2015)

# SCY-078: Ongoing Development Path


Clear path to registration for 1<sup>st</sup> indication: Invasive Candidiasis

- Targeting both primary and salvage treatments in refractory infections
- 4 ongoing workstreams with expected data in 2Q 2016



# SCY-078: Ongoing Phase 2 in IC

- Oral step-down following IV Echinocandin
  - Randomized, open-label, assessing two doses of SCY-078 vs. Standard of Care
  - Primary Endpoints: Safety, Tolerability and Pharmacokinetics
  - Exploratory Endpoints: Efficacy at end of antifungal therapy and relapse rates
  - First patient enrolled in March 2015 → Top-line data for primary endpoints expected to be reported in 2Q 2016




# SCY-078: Ongoing Phase 2 in VVC

---

- Oral treatment for vulvovaginal candidiasis
  - Randomized, evaluator-blinded study
  - Patients with moderate to severe VVC
  - Two dose-regimens of oral SCY-078 (5 or 3 days) compared to standard dose-regimen of Fluconazole
  - Primary Endpoints: Safety and Efficacy (clinical & microbiological outcome) at Day 24
  - Secondary / Exploratory Endpoints: Relapse rates, clinical & microbiological outcomes up to Month 4
  - First patient enrolled in Nov. 2015 → Top-line data for primary endpoints expected to be reported in 2Q 2016

# Timelines and Financial Highlights

---



- \$53.8mm Cash as of 9/30/15 – expected sufficient funds into 1H 2017
- No debt

# SCYX: Highlights

---

- SCY-078, a new antifungal class with a novel combination of attributes:
  - Validated mechanism of action
  - Both IV and oral formulations
  - Activity against Azole- and Echinocandin-resistant strains
  - Targeting multiple indications
  - Data from two Phase 2 studies expected in 2Q 2016
  - Extended market exclusivity and IP protection
- Significant unmet medical needs with global market potential
- Favorable regulatory environment
  - Granted QIDP and Fast Track status
- Experienced management team
- Expected sufficient funds into 1H 2017 - \$53.8mm in cash (as of 9/30/15)

---

NASDAQ: SCYX  
[www.scynexis.com](http://www.scynexis.com)





